Recursion Pharmaceuticals
RXRX
$3.79
+5.57%
Related headlines
RXRX price trend
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Recursion Pharmaceuticals's 12-month outlook, with a consensus price target around $4.93 and implied upside of +30.1% versus the current price.
Average Target
$4.93
2 analysts
Implied Upside
+30.1%
vs. current price
Analyst Count
2
covering this stock
Price Range
$3 - $5
Analyst target range
RXRX Technical Analysis
Beta
1.05
1.05x market volatility
Max Drawdown
-58.2%
Largest decline past year
52-Week Range
$3-$7
Price range past year
Annual Return
-9.3%
Cumulative gain past year
| Period | RXRX Return | S&P 500 |
|---|---|---|
| 1m | +11.8% | +5.3% |
| 3m | +7.1% | +11.5% |
| 6m | -18.7% | +10.9% |
| 1y | -9.3% | +28.7% |
| ytd | -9.8% | +11.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
Valuation Analysis: Is RXRX Overvalued?
PE
-2.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-2.1x
Enterprise Value Multiple